ORG-25935
ORG-25935 is a drug that acts as a serotonin reuptake inhibitor, and was developed for the treatment of depression and anxiety disorders. It was developed by Organon International, a pharmaceutical company based in the Netherlands.
History[edit | edit source]
ORG-25935 was first synthesized by Organon International in the early 2000s. The drug was developed as a potential treatment for depression and anxiety disorders, due to its ability to inhibit the reuptake of serotonin, a neurotransmitter that is often imbalanced in individuals with these conditions.
Mechanism of Action[edit | edit source]
ORG-25935 works by inhibiting the reuptake of serotonin, a neurotransmitter that is involved in mood regulation. By preventing the reuptake of serotonin, ORG-25935 increases the amount of serotonin available in the brain, which can help to alleviate symptoms of depression and anxiety.
Clinical Trials[edit | edit source]
Clinical trials for ORG-25935 were conducted in the mid-2000s. However, the drug did not progress beyond Phase II trials, and its development was discontinued.
See Also[edit | edit source]
References[edit | edit source]
ORG-25935 Resources | ||
---|---|---|
|
|
Translate to: East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski
Navigation: Wellness - Encyclopedia - Health topics - Disease Index - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro) available.
Advertise on WikiMD
WikiMD is not a substitute for professional medical advice. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD